Betahistine is a synthetic histamine analogue (2-[2-(methylamino)ethyl]pyridine) used as an active pharmaceutical ingredient (API) primarily in the treatment of Ménière's disease, a disorder involving vertigo, hearing loss, and tinnitus. It acts by improving blood flow in the inner ear and reducing endolymphatic hydrops, thereby decreasing the frequency and severity of vertigo attacks, as well as associated symptoms like nausea and vomiting. It may also be used for other vestibular disorders and migraines. This product is a light yellow liquid reagent with a purity of 96.5-100%, confirmed by NMR and IR spectroscopy, suitable for pharmaceutical research, synthesis, or formulation.